Campylobacter Fetus Spp. Fetus’a Bağlı Bakteriyemi Olgusu Ve Laboratuvar Tanıda Gram Boyamanın Önemi

Campylobacter fetus subsp. fetus immün sistemin zay f oldu u ki ilerde öncelikle bakteriyemi ve ba rsak d enfeksiyonlarla ili kilidir. Bakteriyemi; septik abortus, septik artrit, apse, menenjit, endokardit, mikotik anevrizma, trombo ebit, peritonit ve salpenjit gibi sistemik komplikasyonlara neden olabilir. Bu çal mada, 92 ya ndaki kronik pyelonefrite sekonder kronik böbrek hastal olan bir erkek hastada muhtemelen gastroenterit ile ba lay p bakteriyemi ile seyreden bir C. fetus subsp. fetus enfeksiyonu olgusu ve laboratuvar tan da kan kültürlerinde Gram boyaman n önemi bildirilmi tir. Kan kültüründen izole edilen C. fetus. subsp. fetus’un E-Test ile antibiyotik duyarl l k testi yap lm ; piperasilin ile piperasilin/tazobaktama dirençli, ampisilin, sefepim, imipenem, meropenem, klaritromisin, levo oksasin, azitromisin, klindamisin, eritromisin, gentamisin ve sipro oksasine duyarl bulunmu tur. Hastan n tedavisinde 2x200 mg sipro oksasilin kullan lm t r

A Case Of Bacteremia Due To Campylobacter Fetus Subsp. Fetus and Importance Of Gram Stain At Laboratory Diagnosis

Campylobacter fetus subsp. fetus is related with bacteriemia and extraintestinal system infections at immunode cient patients. Bacteriemia may cause systemic complications like septic abortus, septic arthritis, abscess, menengitidis, endocarditis, micotic aneurisym, trombophlebitis, peritonitis and salphengitis. In this case report, a 92 years old male patient with secondary chronic renal failure due to chronic pylenophritis developed bacteriemia possibly after a gastrointestinal infection caused by Campylobacter fetus subsp. fetus and importance of Gram stain at laboratory diagnosis by blood cultures were discussed. Antibacterial susceptibility of Campylobacter fetus subsp. fetus isolated from blood culture was determined using E-Test and was found resistant to piperacillin and piperacillin/tazobactam and sensitive to ampicilline, cephepime, imipenem, meropenem, klaritromicin, levo oxacin, azithromycine, erythromycin, gentamicin and cipro oxacin. 2x200 mg of cipro oxacin was used for the treatment of the patient

___

  • Fitzgerald C, Nachamkin I. Campylobacter and Arcobacter. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA eds. Manual of Clinical Microbiology. 9th ed.,Washington, DC: ASM Press, 2007: 933-46.
  • Zonios DI, Panayiotakopoulos GD, Kabletsas EO, Tzima EL, Stefanou I, Archimandritis AJ. Campylobacter fetus bacteraemia in a healty individual: clinical and therapeutical implications. Journal of infection, 2005; 51: 329-32.
  • Decousser JW, Maulcon VP, Bartizel C et al. Fatal relapse of a purulent pleurisy caused by Campylobacter fetus spp. fetus. J Clin Microbiol, 2007; 45: 2334-36.
  • Skirrow MB, Jones DM, Sutcliffe E, Benjamin J. Campylobacter bacteremia in England and Wales, 1981-1991. Epidemiol Infect, 1993; 110: 567-73.
  • Baustaolu AC, Klç A, Özyurt M, Turhan V, Hasçelik G. Campylobacter jejuni spp. jejuni’ye bal bir bakteriyemi olgusu. Türk Hij Den Biyol Derg, 2001; 58: 68-70.
  • Fishbane S. Hematologic aspects of kidney disease. In: Brenner BM ed. Brenner and Rector’s The Kidney. 8th ed., Philadelphia, Saunders Elsevier Press, 2007:1728-43.
  • Clinical and Laboratory Standards Instute. Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement. CLSI Document M100- S16. Wayne, Pennsylvania, USA; 2006.
  • Luber P, Barlet E, Genschow E, Wagner J, Hahn H. Comparison of broth microdilution, E Test, and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni and Campylobacter coli. J Clin Microbiol, 2003; 41: 1062-68.
  • Tremblay C, Gaudreau C, Lorange M. Epidemiology and antimicrobial susceptibilities of 111 Campylobacter fetus subsp. fetus strains isolated in Quebec, Canada, from 1983 to 2000. J Clin Microbiol, 2003; 41: 463-66.